Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
Context: For patients with metastatic papillary thyroid carcinoma (PTC) refractory to radioactive iodine (RAI) treatment, systemic chemotherapy has limited efficacy. Such tumors frequently harbor BRAF V600E, and this alteration may predict responsiveness to vemura-fenib treatment. Objective: We repo...
Main Authors: | Siraj M. Ali, Je He, Wade Carson, Phil J. Stephens, Joseph Fiorillo, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Jeffrey Sharman |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2014-05-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/363377 |
Similar Items
-
Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01) -
The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01) -
Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Elzbieta Nowara, et al.
Published: (2016-02-01) -
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01) -
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)